{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:20Z","timestamp":1787169800214,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To assess whether preoperative bevacizumab (BVZ) in treatment-na\u00efve eyes with proliferative diabetic retinopathy (PDR) and vitreous hemorrhage (VH) without tractional retinal detachment (TRD) leads to lesser macular edema and better visual outcome compared to eyes that do not receive BVZ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This quasi-randomized retrospective study included 217 treatment-na\u00efve eyes with nonclearing VH without TRD that had vitrectomy with or without BVZ and had a minimum 6-months follow-up. Postoperative variables, including visual acuity (BCVA), central macular thickness (CMT) at 1 month, and need for additional anti-VEGF injections till 6 months follow-up, were recorded for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 217 eyes, 107 eyes (49%) received preoperative BVZ and 110 (51%) did not. Groups were comparable in terms of preoperative characteristics. At 1 month, mean CMT was significantly higher in eyes without BVZ (310 \u00b1 33 \u03bc vs. 246 \u00b1 34\u03bc; P &lt; 0.001). The likelihood of developing center-involving DME at 1 month after vitrectomy was 67% lower if the eye received preoperative BVZ (OR = 0.33, 95%CI = 0.18\u20132.54, P = 0.56). Though BCVA improved significantly in both groups at 1 month, it was 1\/3\n                      <jats:sup>rd<\/jats:sup>\n                      of a line better in the BVZ group (\u03b2 coefficient = \u22120.035 logMAR, 95%CI = \u22120.04 to \u22120.008 logMAR, P = 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Preoperative BVZ in treatment-na\u00efve eyes with PDR and VH but without TRD lead to better macular status and marginally improved vision at 1 month, which was maintained at 6 months. In view of these results, patients may be offered BVZ only when it is readily affordable to them.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1264_21","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T12:37:01Z","timestamp":1636634221000},"page":"3283-3287","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of preoperative bevacizumab in diabetics with nonclearing vitreous hemorrhage without tractional detachment \u2013 A quasi-randomized retrospective study"],"prefix":"10.4103","volume":"69","author":[{"given":"Debdulal","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Department of Vitreo-Retina, Disha Eye Hospitals, 88 Ghosh Para Road Barrackpore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Maiti","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Susrut Eye Hospital, Salt Lake, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kelkar","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, National Institute of Ophthalmology,(NIO), Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Future Vision Eye Care and Research Centre, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Susrut Eye Hospital, Salt Lake, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounika","family":"Bolisetty","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, National Institute of Ophthalmology,(NIO), Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Kothari","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, National Institute of Ophthalmology,(NIO), Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydeep","family":"Majumder","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Susrut Eye Hospital, Salt Lake, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/IAE.0000000000001280","article-title":"Pars plana vitrectomy for diabetic macular edema:A systematic review, meta-analysis, and synthesis of safety literature","volume":"37","author":"Jackson","year":"2017","journal-title":"Retina"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ophtha.2009.07.001","article-title":"Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients:A randomized clinical trial","volume":"116","author":"Ahmadieh","year":"2009","journal-title":"Ophthalmology"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1136\/bjo.2010.189514","article-title":"A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy","volume":"95","author":"Zhao","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.sjopt.2016.10.001","article-title":"The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy","volume":"30","author":"Al-Kharashi","year":"2016","journal-title":"Saudi J Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/08820538.2013.835847","article-title":"The effect of intravitreal bevacizumab as a pretreatment of vitrectomy for diabetic vitreous hemorrhage on recurrent hemorrhage","volume":"30","author":"Berk","year":"2015","journal-title":"Semin Ophthalmol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.oret.2018.04.014","article-title":"Bevacizumab before diabetic vitrectomy:A clinical trial assessing 3 dosing amounts","volume":"2","author":"Castillo Velazquez","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"B7-20240828","first-page":"709","article-title":"Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy","volume":"2","author":"El-Batarny","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/IAE.0b013e31820a68e5","article-title":"Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage","volume":"31","author":"Farahvash","year":"2011","journal-title":"Retina"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10792-012-9541-5","article-title":"Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab","volume":"32","author":"Gupta","year":"2012","journal-title":"Int Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40942-021-00296-7","article-title":"Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy:A randomized clinical trial","volume":"7","author":"Jorge","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ophtha.2011.03.036","article-title":"The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy","volume":"118","author":"Ahn","year":"2011","journal-title":"Ophthalmology"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12886-019-1179-x","article-title":"Reoperation following vitrectomy for diabetic vitreous hemorrhage with versus without preoperative intravitreal bevacizumab","volume":"19","author":"Hu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/IAE.0b013e3181a8eb88","article-title":"Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin)","volume":"29","author":"Lo","year":"2009","journal-title":"Retina"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/IAE.0000000000000723","article-title":"Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy:A systematic review and meta-analysis","volume":"35","author":"Simunovic","year":"2015","journal-title":"Retina"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2019.05.007","article-title":"Preoperative bevacizumab for tractional retinal detachment in proliferative diabetic retinopathy:A prospective randomized clinical trial","volume":"207","author":"Arevalo","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"(Suppl)","key":"B16-20240828","first-page":"161","article-title":"Vitrectomy with fibrovascular membrane delamination for proliferative diabetic retinopathy with or without preoperative Avastin","volume":"20","author":"Papavasileiou","year":"2017","journal-title":"Hell J Nucl Med"},{"key":"B17-20240828","first-page":"CD008214","article-title":"Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","volume":"2015","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/2474126417721774","article-title":"The role of perioperative anti-VEGF during vitrectomy for vitreous hemorrhage in relation to postoperative nonclearing vitreous hemorrhage and cystoid macular edema","volume":"1","author":"Nagpal","year":"2017","journal-title":"J Vitreoretin Dis"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.12669\/pjms.325.10362","article-title":"Role of bevacizumab in the prevention of early postoperative haemorrhage after 25-gauge microincision vitrectomy surgery","volume":"32","author":"Sultan","year":"2016","journal-title":"Pak J Med Sci"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"728","DOI":"10.29271\/jcpsp.2019.08.728","article-title":"Visual outcomes of pars plana vitrectomy alone or with intravitreal bevacizumab in patients of diabetic vitreous haemorrhage","volume":"29","author":"Haseeb","year":"2019","journal-title":"J Coll Physicians Surg Pak"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1264_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:13:24Z","timestamp":1787166804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1264_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1264_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"2021-05-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}